ACM
KURA icon

Alethea Capital Management’s Kura Oncology KURA Stock Holding History

Alethea Capital Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-150,000
Closed -$278K – 23
2025
Q3 		$278K Buy
+150,000
New +$1.07M 0.18% 28

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Alethea Capital Management's KURA Position: Q2 2026 in Review

Alethea Capital Management increased its Kura Oncology (KURA) stake by 42% in Q2 2026, buying an estimated $6.02M and bringing the position to 2,167,938 shares worth $23.8M. The position accounts for 9.85% of the portfolio, ranked #3.

Alethea Capital Management first reported a position in KURA in Q2 2016 and has held it in 38 quarters since. 221 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Alethea Capital Management held 2,167,938 shares of Kura Oncology worth $23.8M as of Q2 2026.
  • Alethea Capital Management bought 638,569 Kura Oncology shares in Q2 2026, an estimated $6.02M.
  • Kura Oncology made up 9.85% of Alethea Capital Management's portfolio in Q2 2026, its #3 holding.
  • Alethea Capital Management first reported a position in Kura Oncology in Q2 2016 and has held it in 38 quarters since.
  • 221 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Alethea Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.